Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
暂无分享,去创建一个
Daniel J Sargent | Richard Simon | D. Sargent | R. Simon | T. Fojo | S. Bates | H. Scher | G. Curt | M. Rothenberg | W. Stein | P. Lebowitz | J. Beetsch | R. Simantov | Susan E Bates | Howard I Scher | C. Hugh-Jones | Tito Fojo | Ronit Simantov | Kald Abdallah | Charles Hugh-Jones | Wilfred D Stein | Julia Wilkerson | Greg Curt | Mace Rothenberg | Martin Murphy | Joseph Morrell | Joel Beetsch | Peter Lebowitz | J. Morrell | J. Wilkerson | M. Murphy | K. Abdallah
[1] H. Kantarjian,et al. Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.
[2] L. Thill,et al. Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study , 2010, BJU international.
[3] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[4] T. Fojo,et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. , 2008, The oncologist.
[5] P. Kantoff,et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). , 2015 .
[6] F. André,et al. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Bono,et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.
[8] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[9] T. Fojo,et al. Why do phase III clinical trials in oncology fail so often? , 2012, Journal of the National Cancer Institute.
[10] S. Bates,et al. Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma , 2009, Cancer journal.
[11] Sean Khozin,et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Thierry Gil,et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.
[14] Melissa L. Johnson,et al. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. , 2015, The oncologist.
[15] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .
[16] Albert Lai,et al. Time course of imaging changes of GBM during extended bevacizumab treatment , 2008, Journal of Neuro-Oncology.
[17] M. Burotto,et al. Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example , 2014, PloS one.
[18] D. Gerber,et al. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Fojo,et al. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. , 2008, The oncologist.
[20] T. Fojo,et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. , 2011, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] K C Cain,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Saad,et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[24] P. Albers,et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Antonarakis,et al. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[27] W. Catalona,et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. , 2010, Urology.
[28] S. Bates,et al. Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth , 2012, Clinical Cancer Research.
[29] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) , 2014, BMC Pulmonary Medicine.
[30] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[31] M. Moyad. Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial , 2015 .
[32] R. DiPaola,et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.